Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838361 | 1.00 | AKR1C1 (0.44) | AKR1C1HSD11B1HDAC4PNMTMAOA | |
| SCHEMBL835098 | 0.92 | AKR1C1 (0.55) | AKR1C1HSD11B1HDAC4MEN1KMT2A | |
| SCHEMBL14491581 | 0.87 | ALDH1A1 (0.35) | AKR1C1HSD11B1HDAC4SPHK1MEN1 | |
| SCHEMBL8220769 | 0.80 | MAOB (0.38) | HSD11B1MAOAMAOBSLC22A2SLC22A1 | |
| SCHEMBL17115021 | 0.80 | HSD11B1 (0.45) | HSD11B1HDAC4MAOAMAOBHTR3E | |
| SCHEMBL28842444 | 0.80 | SLC22A2 (0.36) | TAAR1SLC22A2SLC22A1SLC22A3PLAU | |
| SCHEMBL17102004 | 0.80 | MAOB (0.38) | HSD11B1MAOAMAOBSLC22A2SLC22A1 | |
| SCHEMBL28842496 | 0.80 | SLC22A2 (0.36) | SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL21824467 | 0.80 | CA1 (0.42) | KMT2A | |
| SCHEMBL21824468 | 0.80 | CA1 (0.42) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096658-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096654-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096660-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096653-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096662-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096657-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-118994191-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994190-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-114437105-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |
| US-8143264-B2 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GLAXOSMITHKLINE LLC | 2011-10-20 | — | — | US | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| WO-2008050200-A1 | OXADIAZOLE COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007017262-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, XDH, GPR88 | AKR1C1 1232/4885HSD11B1 679/4885HDAC4 4425/4885 |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | AKR1C1 678/4885HSD11B1 528/4885HDAC4 3800/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | AKR1C1 3871/4885HSD11B1 2672/4885HDAC4 1915/4885 |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, GPR88, XDH | AKR1C1 1697/4885HSD11B1 1188/4885HDAC4 4361/4885 |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | XDH, GPR84, GPR88 | AKR1C1 1317/4885HSD11B1 725/4885HDAC4 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.